Equivalent of Form PTO/SB/08a (01-08)

Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		Otige die	r aperwork reduction ract of 1550, if	o persons are required to respond to a coller	SION OF INIONHAUDIT UNIESS IT CONTAINS A VAID OMB CONTO HUM
Substitute for form 1449/PTO		Complete if Known			
FIFTH SUPPLEMENTAL				Application Number	10/633,697
INFORMATION DISCLOSURE				Filing Date	plete if Known 10/633,697 August 5, 2003 UMAÑA, Pablo 1636 GUZO, David
				First Named Inventor	UMAÑA, Pablo
STATEMENT BY APPLICANT				Art Unit	1636
(Use as many sheets as necessary)	Examiner Name	GUZO, David			
Sheet	1	of	1	Attorney Docket Number	1975.0010005/TJS/T-M/M-N

			U.S. PATENT DO		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No.	Number-Kind Code ^{2 (IrKassa)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear

		Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
/D.G./	AL3	AU 2002307037 B2	10/15/2002	Biogen Idec Inc.		Г
		1			ļ	_
						⊢
					ļ	┝
						-
		-				⊢
	-	1				⊢

869821 1 /David Guzo/ Date Examiner 09/19/2008

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).' See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. 'Enter Officite that issued the document, by the two-ledow (WIPD Standard ST.3).' For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if

Considered

English language Translation is attached. English inguige (Frishlation is attached, by 37 CFR. 177 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and file) in collection of information is required by 37 CFR. 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and file) in the collection of information in confidentially to governed by 38. U.S. C. 122 and 37 CFR. 1.1.1 The collection is elemented to file of the 2-branes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for the amount of time you require to complete this form and/or suggestions for the amount of time (buffer) information. Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08b (01-08)

Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
FIFTH SUPPLEMENTAL	Application Number	10/633,697	
	Filing Date	August 5, 2003	
INFORMATION DISCLOSURE	Application Number 10/633,697 Filing Date August 5, 2003 First Named Inventor UMAÑA, Pablo Art Unit 1636 Examiner Name GUZO, David	UMAÑA, Pablo	
STATEMENT BY APPLICANT	Art Unit	1636	
(Use as many sheets as necessary)	Examiner Name	GUZO, David	
Sheet 1 of 1	Attorney Docket Number	1975.0010005/TJS/T-M/M-N	

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AR64	Buske, C., et al., "Monoclonal Antibody Therapy for B Cell Non-Hodgkin's Lymphomas: Emerging Concepts of a Tumour-targeted Strategy," European Journal of Cancer 35:549-557, Elsevier Science Ltd. (1999)	
AS64	Maloney, D.G., et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma," Blood 84:2457-2466, The American Society of Hematology (1994)	
AT64	Novak-Hofer, I., et al., "Cellular Processing of Copper-67-labeled Monoclonal Antibody chCE7 by Human Neuroblastoma Cells," <i>Cancer Research</i> 55:46-50, The American Association for Cancer Research (1995)	
		_
	AS64	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), ettle of the item (book, magazine, journal, serial, symposium, catalog, etc.), datc, page(s), volume-issue number(s), publisher, city and/or country where published Buske, C., et al., "Monoclonal Antibody Therapy for B Cell Non-Hodgkin's Lymphomas: Emerging Concepts of a Tumour-targeted Strategy," European Journal of Cancer 35:549-557, Elsevier Science Ltd. (1999) Maloney, D.G., et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma," Blood 84:2457-2466, The American Society of Hematology (1994) Novak-Hofer, I., et al., "Cellular Processing of Copper-67-labeled Monoclonal Antibody chCE7 by Human Neuroblastoma Cells," Cancer Research 55:46-50,

869819 1 Examiner Date /David Guzo/ 09/19/2008 Signature Considered

Applicant's unique catation designation number (optionals)." Applicant is to place a check mark here it English language Transidion's attached. This collection of information is required by 37 CPR 1.08. The information is required to obtain or relatin a benefit by the public which is to lite (and by the Time collection of information is required by 20 CPR 1.08. The information is required to obtain or relatin a benefit by the public which is to lite (and by the collection) of the collection o

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.